<DOC>
	<DOC>NCT02367066</DOC>
	<brief_summary>A study to assess the Pharmacodynamics of oral AR-C165395XX after Administration of Repeated Doses for 3 days in Subjects with Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)</brief_title>
	<detailed_description>A Single Centre, Double-blind, Randomised, Placebo-controlled, Cross-over Phase I Study to Assess the Pharmacodynamics of oral AR-C165395XX after Administration of Repeated Doses for 3 days in Subjects with Type 2 Diabetes Mellitus</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion Criteria Provision of informed consent Male or female of nonchildbearing potential (postmenopausal, and/or have undergone hysterectomy and/or bilateral oophorectomy or salpingectomy/tubal ligation) aged ≥18. Patients with HbA1c ≥7.5 but ≤11% at enrolment visit (Visit 1) ody mass index &gt;19 to &lt;38 kg/m2 he fasting plasma glucose should be in the range of 314 mmol/L (54252 mg/dL, nclusive) on the morning of Visit 1. Clinical diagnosis of type 2 diabetes mellitus Metformin as only antidiabetic treatment, at least for the last 3 months History or sign of any clinically significant disease or disorder which, in the opinion f the investigator, may either put the subject at risk because of participation in the sudy, or influence the results or the subject's ability to participate in the study Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) laboratory results &gt;3x upper level of normal range (ULN) Clinical diagnosis of Type 1 diabetes mellitus and/or history of diabetic ketoacidosis or positive Glutamic Acid Decarboxylase Autoantibodies test (GAD antibodies test). Patients treated with single Insulin therapy within the last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>patients</keyword>
	<keyword>glycaemic control on metformin</keyword>
</DOC>